NASDAQ:ALGS

Aligos Therapeutics News Headlines

$26.67
-0.31 (-1.15 %)
(As of 06/17/2021 03:42 PM ET)
Add
Compare
Today's Range
$25.06
$27.24
50-Day Range
$20.30
$33.60
52-Week Range
$12.82
$37.51
Volume4,084 shs
Average Volume76,759 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Aligos Therapeutics (NASDAQ ALGS) News Headlines Today

SourceHeadline
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 7.3%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 7.3%
americanbankingnews.com - June 14 at 2:06 PM
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 7.3%Aligos Therapeutics (NASDAQ:ALGS) Trading Down 7.3%
americanbankingnews.com - June 14 at 2:06 PM
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
finance.yahoo.com - June 14 at 1:04 PM
Head-To-Head Contrast: Aligos Therapeutics (ALGS) & Its RivalsHead-To-Head Contrast: Aligos Therapeutics (ALGS) & Its Rivals
americanbankingnews.com - June 13 at 1:08 PM
Aligos Therapeutics (ALGS) & Its Rivals Critical AnalysisAligos Therapeutics (ALGS) & Its Rivals Critical Analysis
americanbankingnews.com - June 12 at 9:22 AM
Aligos Therapeutics (NASDAQ:ALGS) Trading 7.4% Higher Aligos Therapeutics (NASDAQ:ALGS) Trading 7.4% Higher
americanbankingnews.com - June 11 at 1:44 PM
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $29.89Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $29.89
americanbankingnews.com - June 10 at 12:36 PM
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG ConferenceAligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
finance.yahoo.com - June 10 at 8:29 AM
Head-To-Head Contrast: Aligos Therapeutics (ALGS) versus Its CompetitorsHead-To-Head Contrast: Aligos Therapeutics (ALGS) versus Its Competitors
americanbankingnews.com - June 7 at 7:14 AM
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 4.9%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 4.9%
americanbankingnews.com - June 3 at 12:48 PM
Critical Comparison: Aligos Therapeutics (ALGS) & The CompetitionCritical Comparison: Aligos Therapeutics (ALGS) & The Competition
americanbankingnews.com - June 3 at 11:24 AM
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 6%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 6%
americanbankingnews.com - June 2 at 2:44 PM
NASH crash hits another Bay Area fatty liver drug hopefulNASH crash hits another Bay Area 'fatty liver' drug hopeful
bizjournals.com - May 24 at 6:04 PM
Aligos Therapeutics to Present at the Jefferies  Virtual Healthcare ConferenceAligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 20 at 6:38 PM
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial ResultsAligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 9:02 PM
Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
finance.yahoo.com - May 5 at 12:11 PM
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of DirectorsAligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
finance.yahoo.com - April 27 at 7:16 PM
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept StudyAligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
finance.yahoo.com - April 14 at 8:09 AM
Heres Why Were Not Too Worried About Aligos Therapeutics (NASDAQ:ALGS) Cash Burn SituationHere's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
nasdaq.com - April 6 at 6:47 PM
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsAligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 23 at 6:33 PM
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept StudyAligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
finance.yahoo.com - March 10 at 9:00 AM
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic InfectionsAligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
finance.yahoo.com - March 8 at 9:29 AM
Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the LiverAligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
finance.yahoo.com - February 3 at 8:14 AM
Do Insiders Own Lots Of Shares In Aligos Therapeutics, Inc. (NASDAQ:ALGS)?Do Insiders Own Lots Of Shares In Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
finance.yahoo.com - January 16 at 9:21 AM
Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceAligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 9:39 AM
Aligos (ALGS) in Focus: Stock Moves 5.6% HigherAligos (ALGS) in Focus: Stock Moves 5.6% Higher
nasdaq.com - December 17 at 12:22 PM
Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020
finance.yahoo.com - December 17 at 12:22 PM
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASHAligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
finance.yahoo.com - December 7 at 9:28 AM
Aligos Therapeutics, Inc. Common Stock (ALGS)Aligos Therapeutics, Inc. Common Stock (ALGS)
nasdaq.com - December 5 at 1:26 AM
Aligos Therapeutics Inc.Aligos Therapeutics Inc.
barrons.com - November 23 at 6:10 PM
Time to Make a Move? J.P. Morgan Offers 3 Stocks to BuyTime to Make a Move? J.P. Morgan Offers 3 Stocks to Buy
finance.yahoo.com - November 18 at 1:42 PM
Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD’s The Liver Meeting Digital Experience™ 2020Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD’s The Liver Meeting Digital Experience™ 2020
finance.yahoo.com - November 16 at 9:13 AM
Aligos Therapeutics is awarded EUR1.8M VLAIO grant to advance chronic hepatitis B researchAligos Therapeutics is awarded EUR1.8M VLAIO grant to advance chronic hepatitis B research
marketwatch.com - November 13 at 10:00 AM
Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare ConferenceAligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
finance.yahoo.com - November 13 at 10:00 AM
Aligos Therapeutics secures €1.8M grant to advance hepatitis B researchAligos Therapeutics secures €1.8M grant to advance hepatitis B research
seekingalpha.com - November 12 at 1:45 PM
Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B researchAligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research
finance.yahoo.com - November 12 at 8:44 AM
Dosing underway for Aligos Therapeutics hepatitis B candidate in early-stage studyDosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
seekingalpha.com - October 30 at 11:56 AM
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis BAligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
finance.yahoo.com - October 30 at 11:56 AM
Foghorn Therapeutics, the Latest Biotech to Go Public, Rises 13% in Its Market DebutFoghorn Therapeutics, the Latest Biotech to Go Public, Rises 13% in Its Market Debut
barrons.com - October 23 at 11:03 PM
There’s an IPO Party in Biotech. Praxis Precision Led Friday’s Slate With a 62% Pop.There’s an IPO Party in Biotech. Praxis Precision Led Friday’s Slate With a 62% Pop.
finance.yahoo.com - October 23 at 7:57 AM
Hearing-Aid Maker Eargo Soars 87% in Its First Trading DayHearing-Aid Maker Eargo Soars 87% in Its First Trading Day
finance.yahoo.com - October 23 at 7:57 AM
This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.